Enphase Energy, Inc.

Freedom Broker lowered by 22% its target price for Enphase Energy, a mid-cap developer of solar energy solutions. While the company’s third-quarter <a href="https://investor.enphase.com/static-files/6f4421c0-8777-4bc0-8a55-f4f7c3685f07">results</a>&nbsp;significantly beat market expectations, it surprised investors to the downside with its outlook for 2026, which points to a sharp decline in demand.

Freedom cuts target price of energy tech Enphase on dim 2026 guidance

Davide Campari-Milano N.V.

Shares of Davide Campari-Milano N.V., the maker of Campari, Aperol, and Cinzano, <a href="https://finance.yahoo.com/quote/CPR.MI/">fell</a>&nbsp;6% in&nbsp;trading in Milan early today, November 3, after Italian prosecutors <a href="https://www.gdf.gov.it/it/gdf-comunica/notizie-ed-eventi/comunicati-stampa/anno-2025/novembre/sequestro-preventivo-per-un-valore-di-oltre-un-miliardo-di-euro">seized</a>&nbsp;about EUR1.3 billion worth of its stock held by controlling shareholder Lagfin SCA as part of a tax-fraud investigation.

Aperol maker suffers worst drop since April amid Italian tax probe

The Beachbody Company, Inc.

Investors should consider buying shares of micro-cap fitness and nutrition company the <a href="https://thebeachbodycompany.com/overview/default.aspx">Beachbody Company</a>, which has upside of almost 150%, Noble Capital Markets <a href="https://dashboard.channelchek.com/wp-content/uploads/pdf/BODI_20251028_27773.pdf">said</a>&nbsp;in an initiation report. After several years of declining revenue, analysts believe the company is on the cusp of recovery, helped in part by the "current GLP-1 phenomenon."

Noble initiates on Beachbody Company with 'buy' as beneficiary of 'GLP-1 phenomenon'

Crocs, Inc.

Footwear manufacturer Crocs reported the first decline in sales of its namesake brand in five years. Third-quarter revenue for the Crocs brand fell 2.5% year over year to $836 million, the company <a href="https://investors.crocs.com/news-and-events/press-releases/press-release-details/2025/Crocs-Inc--Reports-Third-Quarter-2025-Results/default.aspx">said</a>&nbsp;in the earnings release yesterday, October 30. It is the first drop since the second quarter of 2020, MarketWatch <a href="https://www.marketwatch.com/story/has-crocs-demand-peaked-sales-just-dropped-and-are-expected-to-keep-falling-8d5a5e37?mod=newsviewer_click_seemore">notes</a>. In the current quarter, the company also expects Crocs-brand sales to decline about 3%.

Crocs sales decline for first time since 2020 and are expected to keep falling

Absci Corporation

Applied Digital Corporation

Innodata Inc.

Relay Therapeutics, Inc.

For small-cap stocks, late summer was a turning point. At Jackson Hole, Fed Chair Jerome Powell signaled that the tight monetary policy was nearing an end. For small caps, whose profitability is especially sensitive to borrowing costs, that implied a reset in expectations. Tech added fuel: a pickup in new contracts to build AI data centers and strong demand for products from leaders such as Nvidia, Oracle, and TSMC reinforced the idea that even smaller tech names can ride the ongoing AI boom.

A rising tide lifts all boats: How tech small caps gained from the AI boom in 3Q25

Victoria's Secret & Co.

UBS has <a href="https://seekingalpha.com/news/4510219-victorias-secret-rallies-after-ubs-pitches-the-bull-case">upgraded</a>&nbsp;Victoria’s Secret, one of the world’s best-known lingerie retailers, to “buy,” saying the management is capable of restoring sustainable growth after several years of declining sales. The bank’s target price offers 27% upside.

UBS upgrades Victoria’s Secret to 'buy' on growing conviction in management

Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Shares of biotech company Viking Therapeutics could triple, according to Canaccord Genuity, which in a <a href="https://www.cnbc.com/2025/10/29/biggest-analyst-calls-wednesday-include-nvidia-apple-tesla-datadog.html">coverage initiation</a> called the firm "one of the leading biotech companies in the obesity drug development space," now <a href="https://oninvest.com/article/gde-investoram-iskat-potencial-nyj-hit-na-rynke-preparatov-ot-lisnego-vesa">dominated</a>&nbsp;by Novo Nordisk and Eli Lilly.

Canaccord initiates on obesity drugmaker Viking with 'buy,' sees 200% upside

Douglas Dynamics, Inc.

Freedom Broker recommends clients buy shares of Douglas Dynamics, a small manufacturer of snow-clearing equipment whose stock is up more than 30% year to date. The target price set for Douglas securities is 20% above current quotes. Sustainable growth is supported by well-known brands, a wide dealer network, and a balanced sales structure, analysts say.

Freedom initiates on snowplow maker Douglas with 'buy,' TP implying 20% upside

Zedge, Inc.

Shares of Zedge, a micro-cap company that created an emoji encyclopedia and sells ringtones and wallpapers for cell phones, plummeted more than 24% yesterday, October 28. Investors reacted to the company’s fourth-quarter and fiscal-full-year <a href="https://feeds.issuerdirect.com/news-release.html?newsid=7206297427461208&amp;symbol=ZDGE">earnings</a>, with declines across all key financial indicators. The selloff was not tempered by promises about 2026 as "a year of innovation focused on unlocking growth."

Emoji encyclopedia owner Zedge plunges 24% on disappointing fiscal-2025 results

Serve Robotics Inc.

Symbotic Inc.

NIO Inc.

Motley Fool analyst Leo Sun has <a href="https://www.fool.com/investing/2025/10/28/growth-stocks-that-could-be-10-baggers-in-10-years/">highlighted</a>&nbsp;three undervalued stocks that, in his view, could deliver tenfold returns over the next decade. One of them is small-cap company Serve Robotics, a developer of autonomous delivery robots. The other two are warehouse-automation firm Symbotic and Chinese EV maker Nio.

Motley Fool names three growth stocks with 10x upside over a decade

Avidity Biosciences, Inc.

Novartis AG

Shares of Avidity Biosciences, a small developer of therapies for rare diseases including Duchenne muscular dystrophy, jumped more than 40% yesterday, October 27, to an all-time high. Investors reacted to news that Switzerland’s Novartis <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag-302594703.html">plans</a>&nbsp;to acquire the company at a premium to the market. The move sends a signal to investors in small-cap biotech: pharma majors increasingly prefer to buy externally developed assets rather than build them in-house. More transactions can be expected in the coming months, Noble Capital Markets <a href="https://www.channelchek.com/news-channel/novartis-12-billion-avidity-acquisition-strengthens-its-rare-disease-pipeline-amid-pharma-tariff-uncertainty">said</a>&nbsp;in a post.

Novartis $12 bln deal for Avidity sparks mid-cap biotech rally


Unitil Corporation

Global Water Resources, Inc.

Sky Harbour Group Corporation

Millrose Properties, Inc.

The Fed will announce its interest-rate decision on Wednesday, October 29. Markets <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">expect</a>&nbsp;a 25-basis-point cut to 3.75-4.00%. The prior revision in September reignited the stock market, and analysts <a href="https://en.oninvest.com/article/russell-2000-is-clear-winner-from-fed-rate-cut-reaches-new-all-time-high">called</a>&nbsp;small-caps – represented by the Russell 2000 index – the “clear winner.” The day after the decision, on September 18, the index hit a new all-time high for the first time in four years, jumping 2%. Over the last six months, the <a href="https://finance.yahoo.com/quote/%5ERUT/">Russell 2000</a>&nbsp;is up 28.4%, outpacing the <a href="https://finance.yahoo.com/quote/%5ESPX/">S&amp;P 500</a>, the benchmark for large caps, which is up 23.8% in the same period.

Small caps